Gastrointestinal Cancer | Topics

Durvalumab Plus Tremelimumab Combo Yields OS Improvement for Unresectable HCC
January 19, 2022

Patients with unresectable hepatocellular carcinoma received an overall survival benefit following first-line treatment with durvalumab (Imfinzi) and tremelimumab.

Survival Boost Noted With Addition of Durvalumab to Chemotherapy for BTC
January 19, 2022

When compared with placebo and chemotherapy, durvalumab plus gemcitabine and cisplatin was superior in terms of overall survival in the treatment of advanced biliary tract cancer.

FDA Grants Fast Track Designation to CYNK-101 for HER2+ Gastric/GEJ Cancers
January 18, 2022

CYNK-101 plus standard frontline chemotherapy, trastuzumab, and pembrolizumab has received a fast track designation from the FDA for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.

A New Horizon in Cancer Care: Liquid Biopsy
December 24, 2021

Mehmet Sitki Copur, MD, gives his perspective on liquid biopsies and how they can be utilized in gastrointestinal cancer.

Abstracts From the 18th Annual Meeting of the International Society of Gastrointestinal Oncology
November 17, 2021

The International Society of Gastrointestinal Oncology (ISGIO), hosted by Physicians’ Education Resource, LLC (PER®) presented the latest advances in the field of gastrointestinal cancer research.

FDA Grants Fast Track Designation to TT-00420 for Cholangiocarcinoma
November 03, 2021

Patients with cholangiocarcinoma may derive benefit from treatment with TT-00420, which was recently given a fast track designation by the FDA.

Survival Unaffected From Addition of Ramucirumab or Merestinib to Standard First-Line Chemotherapy for Metastatic Biliary Tract Cancer
November 01, 2021

Patients with locally advanced or metastatic biliary tract cancer who received either ramucirumab or merestinib in addition to standard first-line cisplatin and gemcitabine did not experience further survival benefit, although safety remained tolerable.

First-Line Durvalumab/Chemotherapy Combo Results in Meaningful Survival Benefit in Advanced Biliary Tract Cancer
October 26, 2021

Patients with advanced biliary tract cancer received a clinically meaningful and statistically significant overall survival benefit after being treated with durvalumab and chemotherapy.

Durvalumab Plus Tremelimumab Combo Provides Significant Survival Benefit in First-Line Unresectable Hepatocellular Carcinoma
October 15, 2021

Patients with unresectable hepatocellular carcinoma appeared to benefit from treatment with durvalumab and tremelimumab, according to findings from the phase 3 HIMALAYA trial.

Biologics License Applications Accepted for Nivolumab/Ipilimumab and Nivolumab/Chemo for Unresectable Advanced ESCC
October 04, 2021

Treatment with nivolumab/ipilimumab and nivolumab/chemotherapy has demonstrated efficacy in unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma, with results from the CheckMate-648 trial leading to the acceptance of the regimens’ applications by the FDA.